Pfizer to buy Trillium Therapeutics for $2.2B
Pfizer Inc. announced on Monday it will acquire Trillium Therapeutics Inc. for an implied equity value of $2.2 billion, or $18.50 per share, in cash. The Canadian pharmaceutical company develops cance…
Pfizer Inc. announced on Monday it will acquire Trillium Therapeutics Inc. for an implied equity value of $2.2 billion, or $18.50 per share, in cash. The Canadian pharmaceutical company develops cance…